Stockreport

Azitra doses first subject in Phase Ib Netherton syndrome treatment trial [Yahoo! Finance]

Azitra Inc  (AZTR) 
PDF This trial plans to enrol approximately 12 adults who will receive the treatment twice daily for 14 days. The company previously screened the first subject in its Pha [Read more]